SUPPLEMENTARY DATA

Listing of the TODAY Study Group

The following individuals and institutions constitute the TODAY Study Group (* indicates principal investigator or director):


PROJECT OFFICE  National Institute of Diabetes and Digestive and Kidney Diseases: B. Linder*


©2013 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc12-2420/-/DC1
OTHER  Hospital for Sick Children, Toronto: M. Palmert  Medstar Research Institute, Washington DC: R. Ratner  Texas Tech University Health Sciences Center: D. Dremaine  University of Florida: J. Silverstein
Supplementary Figure 1. TODAY CONSORT Diagram

Assessed for eligibility, n=1211

Excluded, n=284
- Did not meet eligibility criteria, n=234
- Declined to participate, n=50
- Other reason, n=0

Entered run-in, n=927

Excluded, n=228
- Did not meet eligibility criteria, n=122
- Declined to participate, n=50
- Other reason, n=56

Randomized, n=699

Metformin alone
Allocated and administered, n=232
- Withdrew informed consent, n=11
  - Study burden (2)
  - Moved away (2)
  - Safety concerns (1)
  - Family reasons (1)
  - Transportation (1)
  - Dissatisfied or concerned with treatment or care (4)
  - Refused (0)

  - Censored at baseline (did not return for follow-up), n=2
  - Censored due to participant undergoing bariatric surgery, n=2
  - Censored due to participant decision to stay on insulin (started for temporary condition) and not wear, n=0

  - Analyzed for primary outcome, n=232

Metformin plus rosiglitazone
Allocated and administered, n=233
- Withdrew informed consent, n=14
  - Study burden (2)
  - Moved away (0)
  - Safety concerns (0)
  - Family reasons (2)
  - Transportation (3)
  - Dissatisfied or concerned with treatment or care (4)
  - Refused (3)

  - Censored at baseline (did not return for follow-up), n=4
  - Censored due to participant undergoing bariatric surgery, n=1
  - Censored due to participant decision to stay on insulin (started for temporary condition) and not wear, n=1

  - Analyzed for primary outcome, n=233

Metformin plus lifestyle
Allocated and administered, n=234
- Withdrew informed consent, n=10
  - Study burden (5)
  - Moved away (0)
  - Safety concerns (0)
  - Family reasons (2)
  - Transportation (0)
  - Dissatisfied or concerned with treatment or care (3)
  - Refused (0)

  - Censored at baseline (did not return for follow-up), n=2
  - Censored due to participant undergoing bariatric surgery, n=2
  - Censored due to participant decision to stay on insulin (started for temporary condition) and not wear, n=1

  - Analyzed for primary outcome, n=234